Management of Low-grade Squamous Intraepithelial Lesions (LSIL) on Pap Smear

Age-Based Management Algorithms

• For adult women with LSIL on Pap smear, the American College of Obstetricians and Gynecologists recommends follow-up with either HPV DNA testing at 12 months or repeat cytology at 6 and 12 months, with colposcopy if HPV is positive or repeat cytology shows ASC-US or greater 1, 2
• The American College of Obstetricians and Gynecologists recommends follow-up with annual cytological testing for adolescents (≤20 years) 1
• At 12-month follow-up, the American College of Obstetricians and Gynecologists recommends referral to colposcopy only if HSIL or greater is found on repeat cytology in adolescents (≤20 years) 1
• HPV DNA testing is not acceptable for adolescents with LSIL, according to the American College of Obstetricians and Gynecology 1
• For adult women (21-65 years), the American College of Obstetricians and Gynecologists recommends two acceptable management options: HPV DNA testing at 12 months or repeat cytology at 6 and 12 months 2, 3, 1
• If HPV test is positive or repeat cytology shows ASC-US or greater, the American College of Obstetricians and Gynecologists recommends colposcopy 1
• For postmenopausal women, the American College of Obstetricians and Gynecologists recommends acceptable options including "reflex" HPV DNA testing, repeat cytology at 6 and 12 months, or colposcopy 1
• For pregnant women, the American College of Obstetricians and Gynecologists recommends colposcopy as the preferred method, and endocervical curettage is unacceptable during pregnancy 1

Risk Stratification

• LSIL represents a heterogeneous group of lesions with varying risk profiles, according to the American College of Obstetricians and Gynecologists 3

Natural History and Progression

• The American College of Obstetricians and Gynecologists notes a high rate of spontaneous regression in LSIL lesions, with over 90% of LSIL cases regressing within 24 months without treatment 3
• 91% of adolescents and young women clear LSIL within 36 months, according to the American College of Obstetricians and Gynecologists 3
• The risk of progression to CIN 2,3 is relatively low within the first 24 months, as stated by the American College of Obstetricians and Gynecologists 3

Common Pitfalls and Caveats

• The Centers for Disease Control and Prevention recommends ensuring proper documentation of Pap test results and follow-up appointments 4, 5
• The Centers for Disease Control and Prevention suggests developing protocols to identify women who miss follow-up appointments 4, 5
• Do not assume low risk despite LSIL being a relatively mild cytologic abnormality; HPV positivity significantly increases risk, as noted by the American Society for Colposcopy and Cervical Pathology 6

Special Considerations

• If LSIL persists for at least 2 years, either continued follow-up or treatment is acceptable, according to the American College of Obstetricians and Gynecologists 3

HPV Reflex Testing Guidelines for Young Women

Age-Specific Guidelines

• The National Comprehensive Cancer Network recommends conservative management for women aged 21 to 24 years, including specific restrictions on HPV testing 7, 8
• Cotesting (cytology plus HPV) is not recommended for cervical cancer screening in women aged 21 to 29 years, as per the National Comprehensive Cancer Network guidelines 7, 8
• For women aged 21-24 years with LSIL, HPV DNA testing is unacceptable, according to the American College of Obstetricians and Gynecologists 9
• If HPV testing is inadvertently performed in this age group, the results should not influence management, as stated by the American College of Obstetricians and Gynecologists 9

Rationale for This Approach

• The restriction on HPV testing in young women is based on important clinical considerations, including the high prevalence of transient HPV infections and the potential for overtreatment, as noted by the National Comprehensive Cancer Network 7, 8
• Concern about overtreatment of young women whose precancerous lesions are likely to regress is a key factor in the guidelines, as highlighted by the National Comprehensive Cancer Network 7, 8

Appropriate Management

• For a 22-year-old with LSIL, the recommended approach is to follow-up with annual cytologic testing (repeat Pap smear in 12 months), as per the American College of Obstetricians and Gynecologists 9
• At the 12-month follow-up, refer to colposcopy only if HSIL or greater is found, according to the American College of Obstetricians and Gynecologists 9
• At the 24-month follow-up, refer to colposcopy if ASC-US or greater is found, as recommended by the American College of Obstetricians and Gynecologists 9

When HPV Testing IS Appropriate

• HPV reflex testing becomes acceptable for ASC-US (not LSIL) in women aged 21-24 years, as per the National Comprehensive Cancer Network guidelines 7, 8
• For women aged 25-29 years with ASC-US, reflex HPV testing is preferred, according to the National Comprehensive Cancer Network 7, 8
• For women aged 30 years and older, cotesting with HPV is the preferred screening strategy, as recommended by the National Comprehensive Cancer Network 7, 8

Management of LSIL with Unknown HPV Status in Women Aged 30‑65

Immediate Colposcopy Recommendation

• The National Comprehensive Cancer Network (NCCN) 2010 guideline recommends immediate colposcopy for women 30‑65 years who have LSIL on cytology and no HPV test result, because this combination carries a higher risk of high‑grade cervical disease. Evidence level: not specified. 10, 11

Distinction Between Cytologic LSIL and Histologic CIN I

• The NCCN 2010 guideline states that cytologic LSIL is not equivalent to histologic CIN I; therefore, management decisions should be based on the cytology finding rather than assuming a histologic grade. Evidence level: not specified. 10